Helpful Resources

Published Data

New data was published this month in the Journal of the American Academy of Dermatology showing results from an institutional review board-approved survey comparing the propensity for dispensing and dosing calculation errors of HEMANGEOLTM (propranolol hydrochloride oral solution 4.28 mg/mL) versus generic propranolol hydrochloride oral solutions (4 mg/mL and 8 mg/mL) during the treatment of infantile hemangiomas. The survey of 220 pediatric dermatologists and other physicians who treat infantile hemangioma found that medication dispensing and calculation errors are very common among physicians prescribing generic propranolol vs. HEMANGEOLTM.

Click here to see our press release.

Patient Education Materials

Download the HEMANGEOLTM Dosing Chart
You can use this chart as a tool to instruct parents and caregivers on the proper dosing of HEMANGEOLTM.

Download the HEMANGEOLTM Instructions for Use
Parents and caregivers can follow these simple instructions to learn how to properly administer HEMANGEOLTM.

Download the HEMANGEOLTM Patient Brochure
This brochure can answer common questions that parents and caregivers may have about infantile hemangioma and HEMANGEOLTM.

Download the HEMANGEOLTM Patient Access information for your patients
This leaflet has information about the HEMANGEOLTM Patient Access and the $25 co-pay program in both English and Spanish.

Download the full Prescribing Information for HEMANGEOLTM
View this document for more information on HEMANGEOLTM, including indications and usage, dosage and administration, contraindications, as well as warnings and precautions.

Get Adobe® Reader®

Other Resources

Request a Visit If you would like additional information about HEMANGEOLTM, our dedicated representatives are available to answer your questions and provide you with the resources you need to educate parents and caregivers.

Find Support for Your Patients and Their Loved Ones
There are a number of advocacy groups dedicated to providing education and support to parents and caregivers of infantile hemangioma patients.

Video Resources
Find videos about HEMANGEOLTM.

HEMANGEOLTM oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.

HEMANGEOLTM is contraindicated in the following conditions:
  • Premature infants with corrected age <5 weeks
  • Infants weighing less than 2 kg
  • Known hypersensitivity to propranolol or any of the excipients
  • Asthma or history of bronchospasm
  • Heart rate <80 beats per minute, greater than first degree heart block, or decompensated heart failure
  • Blood pressure < 50/30 mmHg
  • Pheochromocytoma
HEMANGEOLTM prevents the response of endogenous catecholamines to correct hypoglycemia and masks the adrenergic warning signs of hypoglycemia, particularly tachycardia, palpitations and sweating.

HEMANGEOLTM can cause hypoglycemia in children, especially when they are not feeding regularly or are vomiting; withhold the dose under these conditions. Hypoglycemia may present in the form of seizures, lethargy, or coma. If a child has clinical signs of hypoglycemia, parents should discontinue HEMANGEOLTM and call their health care provider immediately or take the child to the emergency room.

Concomitant treatment with corticosteroids may increase the risks of hypoglycemia.

HEMANGEOLTM may cause or worsen bradycardia or hypotension. Monitor heart rate and blood pressure after treatment initiation or increase in dose. Discontinue treatment if severe (<80 beats per minute) or symptomatic bradycardia or hypotension (systolic blood pressure <50 mmHg) occurs.

HEMANGEOLTM can cause bronchospasm; do not use in patients with asthma or a history of bronchospasm. Interrupt treatment in the event of a lower respiratory tract infection associated with dyspnea and wheezing.

HEMANGEOLTM may worsen circulatory function in patients with congestive heart failure or increase the risk of stroke in PHACE syndrome patients with severe cerebrovascular anomalies. Investigate infants with large facial infantile hemangioma for potential arteriopathy associated with PHACE syndrome prior to HEMANGEOLTM therapy.

HEMANGEOLTM will interfere with epinephrine used to treat serious anaphylaxis.

The most frequently reported adverse reactions to HEMANGEOLTM (occurring ≥10% of patients) were sleep disorders, aggravated respiratory tract infections, diarrhea, and vomiting. Adverse reactions led to treatment discontinuation in fewer than 2% of treated patients.

The most common ( >3% more often on HEMANGEOLTM than on placebo) adverse reactions reported in the a total of 424 patients treated with HEMANGEOLTM 1.2 mg/kg/day or 3.4 mg/kg/day were sleep disorder (17.5%; 16.1%), bronchitis (8%; 13.4%), peripheral coldness (8%; 6.7%), agitation (8.5%; 4.5%), diarrhea (4.5%; 6.3%), somnolence (5%; 0.9%), nightmare (2%; 6.3%), irritability (5.5%; 1.3%), decreased appetite (2.5%; 3.6%), and abdominal pain (3.5%; 0.4%), respectively.

Adverse events such as cardiac disorders, urticaria, alopecia, hypogylcemia, and bradycardia occurred in less than 1%.

Safety and effectiveness for infantile hemangioma have not been established in pediatric patients greater than 1 year of age.

Please see Full Prescribing Information and Medication Guide .

Important Safety Information